Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Autolus Therapeutics plcNASDAQ: AUTL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $71.6M (cash outflow) rose 2.0% year over year, behind the +21.3% change in trailing-twelve-month net income. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at +24.5% a year.
Context
- Net income amounted to 380.5% of revenue in FY2025, down 1799.9 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$211.98M (-26.3%) for the fiscal year ending Dec 2026, a slowdown from the +30.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$71.6M-20.7% QoQ
- Last fiscal yearDec 2025
- -$287.53M+30.3% YoY
- LTMMar 2026
- -$288.97M+21.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.0% | +7.9% | +5.9 pp |
| 1 year | +30.3% | -26.3% | -56.6 pp |
| 3-year CAGR | +24.5% | -26.1% | -50.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (287.53M) USD
- Year-over-year change
- -30.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (287.53M) | -30.3% |
| FY2024 | 2024-12-31 | (220.66M) | -5.9% |
| FY2023 | 2023-12-31 | (208.38M) | -40.0% |
| FY2022 | 2022-12-31 | (148.84M) | -4.7% |
| FY2021 | 2021-12-31 | (142.1M) | — |
Net Income vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 net income of $288.97M is the largest of the 10 companies compared; the peer median is $107.79M.
- Its year-over-year change of +21.3% is the 3rd highest of 10, against a peer median of -26.1%.
- Net income amounts to 312.1% of revenue for AUTL, versus a peer median of 98.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $288.97M | +21.3% | +24.5% | 312.1% | |
| LTM Mar 2026 | $246.41M | -26.3% | +14.4% | 794858.1% | |
| LTM Mar 2026 | $173.76M | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $133.22M | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $129.91M | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $67.27M | +11.1% | -11.8% | 98.8% | |
| LTM Mar 2026 | $43.6M | +98.3% | -25.7% | 96.7% | |
| LTM Mar 2026 | $9.47M | -39.5% | — | 40.9% | |
| LTM Sep 2026 | $2.81M | -98.7% | -12.6% | 0.2% | |
| Peer median (excluding AUTL) | $107.79M | -26.1% | -14.7% | 98.8% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (287.53M) |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.81M |
| Deferred Income Tax | (72K) | (268K) | (986K) | (185K) | (286K) |
| Stock-Based Compensation | 9.94M | 12.01M | 11.2M | 15.47M | 14.44M |
| Change in Working Capital | 4.14M | 3.97M | 292K | (23.66M) | (52.11M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (24.21M) |
| Inventory | 0 | 0 | 0 | (4.23M) | (40.34M) |
| Accounts Payables | (1.82M) | 22K | (509K) | 1.59M | 1.3M |
| Other Working Capital | 5.95M | 3.95M | 801K | (21.02M) | 11.14M |
| Other Non-Cash Items | 1.77M | 13.4M | 45.72M | 15.04M | 32.1M |
| Operating Cash Flow | (117.86M) | (112.31M) | (145.59M) | (206.27M) | (283.57M) |
| Capital Expenditures | (8.86M) | (10.84M) | (10.99M) | (34.82M) | (27.13M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (359.73M) | (242.62M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 428.21M |
| Other Investing Activities | 0 | 0 | 0 | (12.74M) | (8.09M) |
| Investing Cash Flow | (8.86M) | (10.84M) | (10.99M) | (394.55M) | 158.46M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 245.9M | 163.85M | 0 | 549.98M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 38.16M | 59.76M | (883K) | 39.58M | (4.34M) |
| Financing Cash Flow | 284.06M | 223.61M | (883K) | 589.55M | (4.34M) |
| Effect of Forex Changes | (754K) | (28.38M) | 15.03M | (261K) | 6.28M |
| Net Change in Cash | 156.59M | 72.09M | (142.43M) | (11.53M) | (123.17M) |
| Free Cash Flow | (126.72M) | (123.15M) | (156.57M) | (241.09M) | (310.7M) |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.